Immunotherapy with immune checkpoint inhibitors is standard first-line treatment for advanced renal cell carcinoma (RCC), but ...

The LITESPARK-022 and LITESPARK-011 trials evaluated combination regimens containing belzutifan in patients with advanced clear cell RCC.

Merck Announces KEYTRUDA Plus WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell Renal Cell Carcinoma ...

A study from the University of Michigan Health Rogel Cancer Center and Department of Pathology shows that further testing in ...

As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a ...

Investigators presented initial results from a phase 3 trial of adjuvant durvalumab plus tremelimumab for resected primary renal cell carcinoma (RCC).

The CALYPSO trial showed no improvement in outcomes with savolitinib addition in advanced ccRCC patients previously treated with VEGF-targeted therapy. ORRs were 10% for durvalumab, 28% for durvalumab ...

LUMBERTON — Robeson Community College has stepped up to the plate and hit its first double with the signing of two standout ...

Randolph Community College officially welcomed Dennis Mabe, chief executive officer of Randolph Electric Membership Corp., as ...

RCC commemorates founder M. Krishnan Nair with a lecture by oncologist Ravi Kannan, highlighting advancements in cancer ...

Riverland Community College’s fall 2025 enrollment is up 7.1%, surpassing statewide growth and marking its highest numbers ...

Randolph Community College has been awarded a $7,000 grant from BrassCraft Manufacturing Co. to support student learning in ...